-
2024-520444-42-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2024-520445-23-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2025-522987-34-00
4
2026-03-13
Narcolepsy and Idiopathic Hypersomnia
-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2023-509377-23-00
6
2026-02-13
Patients with currently remitted depressive disorders.
-
2025-521124-29-00
10
2026-02-13
Non-Small Cell Lung Cancer
-
2025-521873-15-00
9
2026-02-09
Metastatic hormone-sensitive prostate cancer
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-520831-18-00
4
2025-12-12
Primary Sjogren’s Disease
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-516252-17-00
3
2025-12-09
Patients with low Vitamin D plasma level
-
2024-517711-70-01
4
2025-12-04
Narcolepsy without Cataplexy (NT2)
-
2025-521398-15-00
5
2025-12-04
Immune system diseases
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2025-522291-83-00
5
2025-11-27
Atopic Keratoconjunctivitis
-
2024-517091-38-00
3
2025-11-25
Head and neck squamous cell carcinoma
-
2024-516234-35-00
9
2025-10-15
Relapsed or Refractory B-Cell Malignancies
-
2023-509175-16-00
5
2025-10-14
Sickle cell disease
-
2024-520156-22-00
4
2025-10-08
Metastatic hormone-sensitive prostate cancer